drugset / Trial / NCT00865423
A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Fasting Conditions
RandomizedCrossoverOpen-label
Summary
The purpose of this study is to compare the relative bioavailability of 800 mg Gabapentin Tablets by Purepac Pharmaceutical Co. with that of 800 mg NEURONTIN® Tablets by Parke-Davis following a single oral dose (1 x 800 mg) in healthy adult volunteers under fasting conditions.
Timeline
- Start
- 2001-02
- Primary completion
- 2001-02
- Completion
- 2001-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gabapentin | Small molecule | 800 mg | Oral |
Indications
No indication recorded.